The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement
Top Cited Papers
- 1 October 2007
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 92 (10) , 1335-1342
- https://doi.org/10.3324/haematol.11305
Abstract
Background and Objectives Diffuse large B-cell lymphomas (DLBCL) are common lymphomas that have been classified into three subgroups on the basis of their patterns of gene expression. The aim of this study was to characterize the clinical, biological, immunophenotypic and cytogenetic features of DLBCL with concurrent t(14;18) and 8q24/c-MYC rearrangement. Design and Methods Sixteen cases of DLBCL with the dual translocation were identified between 1998 and January 2006. The clinical features of these cases were examined and morphological, immunohistochemical, flow cytometric and cytogenetic analyses were performed. Results All patients had aggressive features: B symptoms (81%), ECOG performance status >2 (81%), elevated lactate dehydrogenase (100%), stage IV disease (100%) with at least one extra-nodal localization (bone marrow, blood and central nervous system involvement in 93%, 50% and 50%, respectively) and age-adjusted IPI score of 3 in 81%. Despite intensive chemotherapy regimens (including allogeneic transplants), all patients died of disease progression. Progression-free and overall survival was 4 and 5 months, respectively. Immunophenotyping analysis (CD20, CD10, Bcl-6, Mum-1, Bcl-2 CD138, MIB1, CD19, CD5, CD38 and sIg) was performed and showed DLBCL with a germinal center (GC) profile. Ki-67 staining ranged from 70 to 90%. All cases assessed by cytogenetics analysis [conventional cytogenetic and/or fluorescence in situ hybridization (FISH)] had a complex karyotype. In one case, we identified a 8q24/c-MYC translocation variant never reported in DLBCL before: t(8;9)(q24;p13) and t(14;18)(q32;q21). The BCL-6 rearrangement was investigated by FISH and found to rearranged in four cases. Interpretation and Conclusions In conclusion, DLBCL with concurrent t(14;18) and 8q24/c-MYC rearrangement is a subgroup of GC-DLBCLwith poor outcome. It is worth searching for the coexistence of dual translocations in Bcl-2-positive DLBCL with unusual aggressive presentation.Keywords
This publication has 26 references indexed in Scilit:
- Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyBlood, 2006
- Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell SupportNew England Journal of Medicine, 2004
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004
- Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patientsLeukemia, 2003
- The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemiaBlood, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Alterations of a Zinc Finger-Encoding Gene, BCL-6 , in Diffuse Large-Cell LymphomaScience, 1993
- Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 1990
- Activation of thec-mycOncogene in a Precursor-B-Cell Blast Crisis of Follicular Lymphoma, Presenting as Composite LymphomaNew England Journal of Medicine, 1988
- Characteristic chromosomal abnormalities in biopsies and lymphoid‐cell lines from patients with burkitt and non‐burkitt lymphomasInternational Journal of Cancer, 1976